Le Lézard
Classified in: Health, Science and technology
Subject: ATY

(ARQL) Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a Fair Price?

SAN DIEGO, Dec. 9, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of ArQule, Inc. (NASDAQ: ARQL) breached their fiduciary duties in connection with the proposed sale of the Company to Merck & Co.

On December 9, 2019, ArQule announced that it had signed a definitive merger agreement with Merck. Under the terms of the merger agreement, ArQule shareholders will receive $20.00 in cash per share.

The investigation concerns whether the ArQule board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for ArQule shares of common stock.

If you are a shareholder of ArQule and believe the proposed buyout price is too low or you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Johnson Fistel, LLP
Jim Baker, 619-814-4471

[Click here to join this action]

SOURCE Johnson Fistel, LLP

These press releases may also interest you

at 19:10
Worldwide Business with kathy ireland® has announced an exclusive interview with Rapid Release Technology President Dr. Stanley Stanbridge and Vice President of Sales and Marketing Jeff Maier to discuss their innovative technology, High-Speed...

at 19:02
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") .  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation...

at 18:52
BERG, a biopharmaceutical company that merges biology with technology to map and identify drivers of diseases, today announced the presentation of initial results from a Phase 2 clinical trial at the Gastrointestinal Cancer Symposium (ASCO-GI), being...

at 18:34
Most Sacred Heart of Jesus Cardiology and Valvular Institute Medical Director Dr. Nalini Rajamannan has requested the Mayor's office to send the FDA Affidavit outlining Illinois and Minnesota patient testimonies to the Illinois and Chicago Department...

at 18:29
Today, Illinois Governor J.B. Pritzker signed legislation that will cap insulin co-pays. Senate Bill 667 (SB 667) also requires the Illinois Department of Insurance to issue a report that includes a summary of insulin pricing practices as well as...

at 18:20
Shoreline Periodontics' final module of the 2019 Synergy Study Club was recently held in Mystic, CT. Hosted by the practice's periodontists, Drs. Gregory Toback and Marianne Urbanski, the goal of the course is to help educate attending dentists and...

News published on 9 december 2019 at 07:37 and distributed by: